Stock BIOSGN BIOSERGEN AB
Add to a list
To use this feature you must be a member
Log inSign up

News Biosergen AB

Equities

BIOSGN

SE0016013460

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-06-26 EDT 		5-day change 1st Jan Change
0.303 SEK -0.33% Intraday chart for Biosergen AB -5.02% -65.57%
06-14 Biosergen AB Approves Board Changes CI
06-11 Biosergen AB Receives the Final Permission Required to Test Lead Candidate BSG005 in Patients with Invasive Fungal Infection CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bulletin from the annual general meeting on June 14, 2024 in Biosergen AB
AQ
Biosergen AB Approves Board Changes
CI
Biosergen to welcome two new board members based on election at the Annual General Meeting
AQ
Biosergen receives the final permission required to test lead candidate BSG005 in patients with invasive fungal infection.
AQ
Biosergen AB Receives the Final Permission Required to Test Lead Candidate BSG005 in Patients with Invasive Fungal Infection
CI
BioStock: Biosergen towards first-in-patient trial with antifungal therapy
AQ
Biosergen publishes interim report for first quarter 2024
AQ
Biosergen AB Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Notice of annual general meeting in Biosergen AB
AQ
BioStock: Biosergen's CEO - "this is a global health threat and it needs attention"
AQ
Biosergen publishes 2023 annual report
AQ
Conversion of paid subscribed units and first day of trading with warrants of series TO3
AQ
Biosergen to Issue New Units as Compensation Under Rights Issue
MT
Biosergen resolves on a directed issue to underwriters in connection with the completed rights issue
AQ
Biosergen Raises SEK26.4 Million via Rights Issue
MT
Biosergen announces the outcome in the rights issue
AQ
BioStock Investor Pitch: Biosergen
AQ
Members of the board of directors and management subscribe in ongoing rights issue
AQ
Research update Biosergen: Rights issue to fund crucial step for lead project
AQ
BioStock: Rights issue to give Biosergen first in-human efficacy data
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIOSGN Stock
  4. News Biosergen AB